Skip to main content
S&P 5007,637.67+1.14%DOW51,792.27+0.64%NASDAQ26,407.43+1.65%BTC$76,512.00+1.48%ETH$2,450.70+2.78%GOLD$4,391.30+0.09%OIL$101.30-1.10%
Smart Investors Daily
Treace Medical Concepts, Inc. logo

NASDAQ · TMCI

Treace Medical Concepts, Inc.

Healthcare · Medical - Devices

$4.56

Down-$0.05 (-1.15%)

Updated Sep 17, 2026, 7:07 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
183.56M
P/E ratio
-3.7
Dividend yield
0.00%
52-week range
$1.17 – $5.20
Volume
165.59K
Avg. volume
634.64K

Price performance

TMCI price history

1M range · 20 trading sessions · Daily adjusted prices

TMCI closed at $4.56 after 20 trading sessions, up 0.00% for the selected period.

Last close
$4.56
Period change
+0.00%
Period low
$4.34
Period high
$4.88
Daily close
View OHLC price history
TMCI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$4.57$4.625$4.49$4.56165.59K
Sep 15, 2026$4.58$4.615$4.43$4.58161.52K
Sep 14, 2026$4.44$4.665$4.435$4.63230.24K
Sep 11, 2026$4.555$4.555$4.365$4.51147.54K
Sep 10, 2026$4.46$4.52$4.31$4.35223.5K
Sep 9, 2026$4.62$4.725$4.50$4.53113.56K
Sep 8, 2026$4.75$4.85$4.52$4.63267.92K
Sep 4, 2026$4.82$4.89$4.72$4.81231.83K
Sep 3, 2026$4.74$4.93$4.655$4.88275.36K
Sep 2, 2026$4.59$4.86$4.57$4.70172.39K
Sep 1, 2026$4.65$4.689$4.55$4.60254.46K
Aug 31, 2026$4.60$4.785$4.58$4.70260.96K
Aug 28, 2026$4.65$4.785$4.55$4.65237.1K
Aug 27, 2026$4.72$4.78$4.405$4.60226.05K
Aug 26, 2026$4.78$4.80$4.59$4.72217.75K
Aug 25, 2026$4.70$5.01$4.58$4.81595.11K
Aug 24, 2026$4.34$4.40$4.25$4.37348.15K
Aug 21, 2026$4.46$4.54$4.275$4.34277.51K
Aug 20, 2026$4.50$4.51$4.30$4.46271.1K
Aug 19, 2026$4.46$4.62$4.37$4.56398.36K

Latest TMCI news

The latest Smart Investors Daily articles mentioning TMCI.

Stock researchCompany · Overview

TMCI research

Overview

Company profile and research snapshot.

Company profile

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
TMCI recent ratings
DateFirmRatingTarget
Aug 10, 2026Truist SecuritiesHold—
Jul 16, 2026Truist SecuritiesHold—
Mar 2, 2026Lake StreetBuy—
Jan 7, 2026StifelHold—
Dec 18, 2025Truist SecuritiesHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 15, 2026

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacenciesPONTE VEDRA, Fla., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced it will highlight multiple new product innovations and present clinical data at the American Orthopaedic

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By